UNC Lineberger Comprehensive Cancer Center researchers demonstrated that a novel combination of Pfizer’s Ibrance (palbociclib) and Millennium Pharmaceuticals’ sapanisertib, delivered in a nanoparticle formulation, extended the survival of mice with medulloblastoma.
To access this subscriber-only content please log in or subscribe.
If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.
Login Subscribe
If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.
Login Subscribe